S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
OTCMKTS:BIOVF

Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Forecast, Price & News

$20.80
+0.85 (+4.26%)
(As of 09/29/2023 08:54 PM ET)
Compare
Today's Range
$20.80
▼
$20.80
50-Day Range
$18.35
▼
$20.80
52-Week Range
$18.25
▼
$26.48
Volume
1,100 shs
Average Volume
755 shs
Market Capitalization
$6.14 billion
P/E Ratio
21.22
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort Interest

BIOVF stock logo

About Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Stock

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

BIOVF Price History

BIOVF Stock News Headlines

September 26, 2023 | americanbankingnews.com
Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Price Target Raised to SEK 280 at Morgan Stanley
September 15, 2023 | finance.yahoo.com
Reminder: Sobi KOL investor event: Advancing the standard of care in haemophilia
October 2, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
September 8, 2023 | finance.yahoo.com
Sobi KOL investor event: Advancing the standard of care in haemophilia
August 29, 2023 | finance.yahoo.com
Is Swedish Orphan Biovitrum (BIOVF) Stock Undervalued Right Now?
August 22, 2023 | finance.yahoo.com
Sobi resolves on a rights issue of approximately SEK 6,024 million
August 15, 2023 | finance.yahoo.com
Bulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM)
July 19, 2023 | tmcnet.com
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
October 2, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
July 18, 2023 | finance.yahoo.com
Swedish Orphan Biovitrum (BIOVF) Beats Q2 Earnings and Revenue Estimates
July 18, 2023 | prnewswire.com
Sobi publishes Q2 2023 report: Growth and pipeline expansion
July 17, 2023 | markets.businessinsider.com
Swedish Orphan Biovitrum AB earnings: here's what Wall Street expects
July 14, 2023 | finance.yahoo.com
Sobi KOL investor event: the journey for Vonjo®
July 11, 2023 | finance.yahoo.com
Invitation: Sobi's Q2 2023 report
June 25, 2023 | finance.yahoo.com
Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing
June 24, 2023 | finance.yahoo.com
Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
June 20, 2023 | finance.yahoo.com
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme
June 2, 2023 | finance.yahoo.com
Sobi to present new data at the 2023 EHA congress
May 30, 2023 | finance.yahoo.com
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
May 30, 2023 | finance.yahoo.com
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
May 19, 2023 | finance.yahoo.com
EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A
May 10, 2023 | finance.yahoo.com
Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology
May 9, 2023 | finance.yahoo.com
Bulletin from Swedish Orphan Biovitrum (Sobi)'s Annual General Meeting (AGM)
April 27, 2023 | msn.com
Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK3.60, revenue of SEK5.24M
April 27, 2023 | finance.yahoo.com
Swedish Orphan Biovitrum (BIOVF) Q1 Earnings and Revenues Beat Estimates
April 27, 2023 | finance.yahoo.com
Sobi publishes Q1 2023 report: Continued solid progress
April 26, 2023 | markets.businessinsider.com
What Wall Street expects from Swedish Orphan Biovitrum AB's earnings
See More Headlines
Receive BIOVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

BIOVF Company Calendar

Last Earnings
7/18/2023
Today
10/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BIOVF
CUSIP
N/A
CIK
N/A
Web
www.sobi.com
Phone
(468) 697-2000
Fax
N/A
Employees
1,612
Year Founded
2001

Profitability

EPS (Most Recent Fiscal Year)
$0.98
Trailing P/E Ratio
21.22
Forward P/E Ratio
23.11
P/E Growth
N/A
Net Income
$261.43 million
Net Margins
15.52%
Pretax Margin
19.83%
Return on Equity
12.20%
Return on Assets
5.65%

Debt

Debt-to-Equity Ratio
0.61
Current Ratio
0.59
Quick Ratio
0.37

Sales & Book Value

Annual Sales
$1.86 billion
Price / Sales
3.29
Cash Flow
$1.88 per share
Price / Cash Flow
11.05
Book Value
$8.91 per share
Price / Book
2.33

Miscellaneous

Outstanding Shares
295,150,000
Free Float
N/A
Market Cap
$6.14 billion
Optionable
Not Optionable
Beta
0.47

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Guido Oelkers (Age 58)
    CEO & Pres
  • Mr. Henrik Stenqvist (Age 56)
    Chief Financial Officer
  • Mr. Torbjörn Hallberg (Age 54)
    Gen. Counsel & Head of Legal Affairs
  • Mr. Daniel Rankin (Age 43)
    Head of Strategy & Corp. Devel.
  • Pablo de Mora (Age 55)
    Head of Global Marketing & Access
  • Ms. Lena Bjurner (Age 55)
    Head of HR
  • Mr. Armin Reininger M.D. (Age 66)
    Ph.D., Sr. Scientific & Medical Advisor
  • Mr. Norbert Oppitz (Age 56)
    Head of International
  • Mr. Sofiane Fahmy (Age 51)
    Head of Europe
  • Mr. Duane H. Barnes (Age 63)
    Head of North America

Key Competitors

View All Competitors













BIOVF Stock - Frequently Asked Questions

Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOVF shares.
View BIOVF analyst ratings or view top-rated stocks.

How have BIOVF shares performed in 2023?

Swedish Orphan Biovitrum AB (publ)'s stock was trading at $21.15 at the beginning of the year. Since then, BIOVF stock has decreased by 1.7% and is now trading at $20.80.
View the best growth stocks for 2023 here.

Are investors shorting Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in August. As of August 31st, there was short interest totaling 305,200 shares, an increase of 34.9% from the August 15th total of 226,200 shares. Based on an average daily trading volume, of 300 shares, the short-interest ratio is currently 1,017.3 days.
View Swedish Orphan Biovitrum AB (publ)'s Short Interest.

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) posted its earnings results on Tuesday, July, 18th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.03. The business had revenue of $463.04 million for the quarter, compared to analyst estimates of $397.52 million. Swedish Orphan Biovitrum AB (publ) had a trailing twelve-month return on equity of 12.20% and a net margin of 15.52%.

What is Swedish Orphan Biovitrum AB (publ)'s stock symbol?

Swedish Orphan Biovitrum AB (publ) trades on the OTCMKTS under the ticker symbol "BIOVF."

How do I buy shares of Swedish Orphan Biovitrum AB (publ)?

Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Swedish Orphan Biovitrum AB (publ)'s stock price today?

One share of BIOVF stock can currently be purchased for approximately $20.80.

How much money does Swedish Orphan Biovitrum AB (publ) make?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) has a market capitalization of $6.14 billion and generates $1.86 billion in revenue each year. The company earns $261.43 million in net income (profit) each year or $0.98 on an earnings per share basis.

How many employees does Swedish Orphan Biovitrum AB (publ) have?

The company employs 1,612 workers across the globe.

How can I contact Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ)'s mailing address is Tomtebodavagen 23 A Solna, Stockholm V7, SE-112 76. The official website for the company is www.sobi.com. The company can be reached via phone at (468) 697-2000 or via email at shrrelations@bnymellon.com.

This page (OTCMKTS:BIOVF) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -